Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MDS 2024 | The challenges with accurately diagnosing and risk-stratifying patients with MDS

Klaus Metzeler, MD, University of Leipzig, Leipzig, Germany, provides insight into the diagnosis and risk stratification of patients with myelodysplastic syndromes (MDS) and outlines some limitations of the currently accepted WHO/ICC classification system. Classification systems exist to define disease entities; however, groups of patients with biologically similar diseases often may not have the same prognosis, suggesting prognostic classification is also needed. Patients can further be stratified to aid in treatment decisions and allow clinicians to adopt a risk-adapted treatment strategy. Dr Metzeler emphasizes that clinicians must get used to an increasing level of complexity as classification systems (and the definition of MDS itself) continue to evolve. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultancy: Celgene/BMS, Janssen, Novartis, Otsuka, Pfizer; ​Honoraria: AbbVie, Astellas, Celgene/BMS, Janssen, Menarini StemLine, Novartis, Pfizer​.